Research Alliance Corp III

RACC

Market cap $105M

11.54 USD

+0.10

0.87%

At close Updated Sep 8, 4:00 PM EDT

1 day

0.87%

5 days

-44.12%

1 month

-51.92%

3 months

10.96%

6 months

12.04%

Year to date

12.04%

1 year

12.04%

5 years

12.04%

10 years

12.04%

About: Research Alliance Corporation III is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Financials Shell Companies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Neutral

GlobeNewsWire

1 month ago

Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome

Transaction to provide Oak Hill Bio with approximately $175 million in gross proceeds, including $75 million of cash in Research Alliance Corporation III's (Nasdaq: RACC) (“RACC”) trust account that is fully backstopped by RA Capital Management and a $100 million committed private financing. Together with Oak Hill Bio's recent $32.5 million Series A financing, the transaction is expected to provide cash runway for development of rugonersen, a potential best-in-class antisense oligonucleotide (ASO) for the treatment of Angelman syndrome, through Phase 3 readout and potential new drug application (NDA) submission in 2H2029.

See News Rankings

Price charts implemented using Lightweight Charts™

Research Alliance Corp III RACC Market cap $105M

News

Research Alliance Corp III

RACC

Market cap $105M